Phase II - The JILL Study Argenta Merck - Protocol Number S21068-00: Evaluation of field safety and effectiveness of a novel oral JAK-1 inhibitor (AH386526 30 mg/g oral tablets for dogs) compared to active control for the control of atopic dermatitis in d